Cargando…
Hematological differences between patients with different subtypes of sickle cell disease on hydroxyurea treatment
OBJECTIVE: Sickle cell anemia and the interaction S/Beta thalassemia differ in hematological values due to microcytosis and hypochromia caused by the thalassemic mutation. The clinical benefit of long-term hydroxyurea treatment is undeniable in sickle cell disease with monitoring of the biological a...
Autores principales: | Neves, Fabia, Menezes Neto, Osvaldo Alves, Polis, Larissa Bueno, Bassi, Sarah Cristina, Brunetta, Denise Menezes, Silva-Pinto, Ana Cristina, Angulo, Ivan Lucena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Associação Brasileira de Hematologia e
Hemoterapia
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3545429/ https://www.ncbi.nlm.nih.gov/pubmed/23323066 http://dx.doi.org/10.5581/1516-8484.20120107 |
Ejemplares similares
-
Sickle cell disease and pregnancy: analysis of 34 patients followed at the Regional Blood Center of Ribeirão Preto, Brazil
por: Silva-Pinto, Ana Cristina, et al.
Publicado: (2014) -
Intrahepatic Cholestasis in Sickle Cell Disease: A Case Report
por: Brunetta, Denise Menezes, et al.
Publicado: (2011) -
Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia
por: Keikhaei, Bijan, et al.
Publicado: (2016) -
Hydroxyurea Treatment for Sickle Cell Disease
por: Steinberg, Martin H.
Publicado: (2002) -
The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea
por: da Silva, Luiz Bernardino Lima, et al.
Publicado: (2012)